期刊文献+

Relationship of the plasma urotensin Ⅱ with proadrenomedullin N-terminal 20 peptide in patients with congestive heart failure

Relationship of the plasma urotensin Ⅱ with proadrenomedullin N-terminal 20 peptide in patients with congestive heart failure
下载PDF
导出
摘要 Objective: To understand the role of urotensin Ⅱ(UⅡ) and proadrenomedullin N-terminal 20 peptide (PAMP), a fragment of proadrenomedullin (proADM) possessing biological activity, in the pathophysiological process of congestive heart failure (CHF) by observing the variation of their plasma levels and exploring their interrelations. Methods: Plasma UⅡ and PAMP levels were measured by radioimmunoassay in 52 patients with CHF and 14 healthy subjects. Left ventricular ejection fraction (LVEF) and the ratio of E/A were determined by echocardiography. Results: The plasma UⅡ level was significantly lower in patients with CHF than the healthy subjects (1.5±1.0 pg/ml vs 4.3±1.2 pg/ml, P<0.05), while plasma PAMP level was significantly higher in the former group (30.6±5.8 pg/ml vs 21.0±6.6 pg/ml P<0.05). The levels of UⅡ and PAMP were parallel with the severity of CHF, and significant correlation of plasma levels of UⅡ with LVEF (r=0.530, P=0.000) and the ratio of E/A (r=0.618, P=0.000) was noted. LVEF and ratio of E/A were found to be inversely correlated with plasma PAMP levels in the patients (r=-0.568, P=0.000; r=-0.350, P=0.004). Also found was the significant correlation between plasma UⅡ and PAMP levels (r=-0.528, P=0.000). The treatment of the patients resulted in increased plasma UⅡ levels and lowered PAMP levels. Conclusion: The variations of plasma levels of UⅡ and PAMP are parallel with the severity of CHF, suggesting their cooperative actions in the pathophysiology of CHF. Objective: To understand the role of urotensin Ⅱ ( U Ⅱ ) and proadrenomedullin N-terminal 20 peptide ( PAMP) , a fragment of proadrenomedullin ( proADM ) possessing biological activity, in the pathophysiological process of congestive heart failure (CHF) by observing the variation of their plasma levels and exploring their interrelations. Methods: Plasma U Ⅱ and PAMP levels were measured by radioimmunoassay in 52 patients with CHF and 14 healthy subjects. Left ventricular ejection fraction (LVEF) and the ratio of E/A were determined by echocardiography. Results: The plasma U Ⅱ level was significantly lower in patients with CHF than the healthy subjects (1.5±1.0 pg/ml vs 4. 3±1.2 pg/ml, P < 0.05), while plasma PAMP level was significantly higher in the former group (30. 6±5. 8 pg/ml vs 21.0±6.6 pg/ml P < 0. 05 ). The levels of U Ⅱ and PAMP were parallel with the severity of CHF, and significant correlation of plasma levels of U Ⅱ with LVEF (r=0.530, P=0.000) and the ratio of E/A (r=0.618, P = 0. 000) was noted. LVEF and ratio of E/A were found to be inversely correlated with plasma PAMP levels in the patients ( r = - 0. 568, P = 0. 000; r = - 0. 350, P ?0. 004 ) . Also found was the significant correlation between plasma U Ⅱ and PAMP levels (r= -0.528, P = 0. 000) . The treatment of the patients resulted in increased plasma U Ⅱ levels and lowered PAMP levels. Conclusion: The variations of plasma levels of U Ⅱ and PAMP are parallel with the severity of CHF, suggesting their cooperative actions in the pathophysiology of CHF.
出处 《Journal of Medical Colleges of PLA(China)》 CAS 2003年第4期258-261,共4页 中国人民解放军军医大学学报(英文版)
基金 This study is a subitem of Key Basic Research and Development Project of National "973" Program of China (G200056905 )
关键词 congestive heart failure Urotensin n proadrenomedullin N-terminal 20 peptide 充血性心力衰竭 乌洛腾生Ⅱ PAMP 左心室射血分数
  • 相关文献

参考文献9

  • 1Baig MK;Mahon N;McKenna WJ.The pathophysiology of advanced heart failure[J],1999(02).
  • 2New RB;Sampson AC;King, MK.Effects of combined angiotensin Ⅱ and endothelin receptor blockade with developing heart failure: Effects on left ventricular performance,2000(12).
  • 3MacLean MR;Alexander D;Stirrat A.Contractile responses to human urotensin- Ⅱ in rat and human pulmonary arteries: Effect of endothelial factors and chronic hypoxia in the rat[J],2000(02).
  • 4Ames RS;Sarau HM;Chambers JK.Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14[J],1999(6750).
  • 5Douglas SA;Tayara L;Ohlstein EH.A Congestive heart failure and expression of myocardial urotensin Ⅱ[J],2002(9322).
  • 6Kitamura K;Kangawa K;Kawamoto M.Adrenomedullin: A novel hypotensive peptide isolated from human pheochromocytoma[J],1993(02).
  • 7Kitamura K;Sakata J;Kangwa K.Cloning and characterization of cDNA encoding a precusor for human adrenomedullin[J],1993(02).
  • 8Shimosawa T;Fujita T.Hypotensive effect of a newly identified peptide,proadrenomedullin N-terminal 20 peptide,1996(03).
  • 9Etoh T;Kato J;Takenaga M.Differential hormonal profiles of adrenomedullin and proadrenomedullin N-terminal 20 peptide in patients with heart failure and effect of treatment on their plasma levels[J],1999(02).

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部